1. Inhibitory Antibodies
  2. Teplizumab

Teplizumab  (Synonyms: MGA-031; PRV-031)

Cat. No.: HY-P99222

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.

For research use only. We do not sell to patients.

Teplizumab Chemical Structure

Teplizumab Chemical Structure

CAS No. : 876387-05-2

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes[1][2].

IC50 & Target

CD3[1]

In Vitro

Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation[3].
Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs)[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: Human PBMCs
Concentration: 10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL.
Incubation Time: 5 days
Result: Induced cell proliferation (measured by incorporation of [3H]thymidine in a 5-day assay.
In Vivo

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)[1]
Dosage: 0.24 mg/kg, 5 μg
Administration: Intraperitoneal injection (i.p.)
Result: Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.
Decreased circulating hCD4 cells in the peripheral blood.
Decreased in the proportion of T cells in the bone marrow and lung.
Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
Clinical Trial
CAS No.
SMILES

[Teplizumab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Teplizumab
Cat. No.:
HY-P99222
Quantity:
MCE Japan Authorized Agent: